ONO PHARMACEUTICAL CO.,LTD.

October 10, 2018

U.S. Food and Drug Administration Accepts Karyopharm's New Drug Application for Selinexor and Grants Priority Review

This information is intended to notify the press release issued on October 5 (ET) by Karyopharm Therapeutics Inc. Please click http://investors.karyopharm.com/press-releases for the original press release distributed by Karyopharm.

1st paragraph of the press release:

NEWTON, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug Application (NDA) seeking accelerated approval for selinexor, its first in class, oral SINE compound, as a new treatment for patients with penta-refractory multiple myeloma. The FDA also granted Karyopharm's request for Priority Review and assigned an action date of April 6, 2019 under the Prescription Drug User-Fee Act (PDUFA). In its acceptance letter, the FDA has stated that it is currently planning to hold an advisory committee meeting to discuss this application.

About the Ono and Karyopharm Collaboration

In October 2017, Ono Pharmaceutical Co., Ltd. concluded an exclusive license agreement with Karyopharm Therapeutics Inc. for the development and commercialization of Selinexor, their first-in-class oral XPO1 (Exportin 1) inhibitor, and KPT-8602, a second-generation oral XPO1 inhibitor, for all oncology indications exclusively in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries.

Selinoxor (ONO-7705) is now under Phase I study in Japan for the treatment of multiple myeloma and non-Hodgkin lymphoma.

Contacts:
ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
public_relations@ono.co.jp